Slide 1: Aroa Biosurgery (ARX) – Full Year Results May 2025
Aroa Biosurgery (ARX) – Full Year Results May 2025 | Confidential. Not for distribution. UNLOCKING REGENERATIVE HEALING FOR EVERYBODY 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation (Presentation) is dated 29 May 2025 and has been prepared by presentation in conjunction with AROA’s other periodic and continuous disclosure Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 announcements lodged with ASX and
Slide 3: Contents
01 04 03 05 02 Contents Outlook Strategy Overview Financials Operations 3 Confidential. | For Notpurposes educational only. Not for distribution. for distribution.
Slide 4: Overview
Overview 4 | Confidential. Not for distribution.
Slide 5: Unlocking Regenerative healing for everybody
Unlocking Regenerative healing for everybody. World-leading outcomes Unmatched value Widespread impact | Confidential. Not for distribution. 5
Slide 6: AROA at a Glance
AROA at a Glance Well established high-growth soft tissue regeneration company Four product AROA ECM platform families for new products, line >US$3B1 TAM predominantly sold to extensions for existing products US hospitals US Direct (AROA) & Commercial partner 7 million+ AROA products applied >100 (T
Slide 7: Financials
Financials 8 | Confidential. Not for distribution.
Slide 8: FY25 Financial Results
FY25 Financial Results1 NZ$84.7m 86% Total Revenue vs. guidance NZ$81-84m Product Gross Margin NZ$4.2m NZ$22.0m Normalised EBITDA2 | Confidential. Not for distribution. vs. guidance NZ$2-4m Cash Balance 1. Results are presented on a reported basis. 2. Normalised EBITDA is non-conforming financial in
Slide 9: Aroa product sales – FY25
Aroa product sales – FY25 Total Product Revenue to AROA (NZ$) Total Revenue for AROA Products (US$) Total Sales Total Sales 90 100 14% YoY growth 24% YoY growth 80 90 70 80 22% YoY growth 70 60 60 50 NZ$m US$m 50 12% YoY growth 40 40 30 38% YoY growth 30 20 20 35% YoY growth 10 10 0% YoY growth 0% Y
Slide 10: Myriad sales metrics
Myriad sales metrics Average account value (NZ$) and No. of customers Myriad Salespeople $140,000 250 60 7% YoY growth $120,000 200 50 $100,000 40 150 $80,000 30 $60,000 100 20 $40,000 50 $20,000 10 $- 0 0 | Confidential. Not for distribution. FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Avg. accoun
Slide 11: Financial Results
Financial Results H1 FY25 H2 FY25 FY25 YoY % Reported Reported Reported • Total revenue stepped up NZ$39.2m NZ$45.5m NZ$84.7m +23% in H2 Total Revenue Total Revenue Total Revenue • Myriad sales ~18% growth on H1 87% 85% 86% +100 bps • Sales to TELA ~15% growth Product Gross Product Gross Product Gro
Slide 12: Cash flow
Cash flow H1 FY25 H2 FY25 FY25 Reported Reported Reported YOY% • Positive operating (NZ$4.9m) NZ$2.3m (NZ$2.6m) Operating 65% cash flows in H2 Operating Operating decrease in out flow activities activities activities • Total net cash flow breakeven in H2 (NZ$2.9m) (NZ$2.2m) (NZ$5.1m) • Cash balance
Slide 13: Use of Funds
Use of Funds Sales & Marketing Expenses R&D Spend (% of product revenue) 12% YoY growth 20% 17% 40 12 13% 21% 30 9 30% NZ$m NZ$m 6 23% 20 3 10 0 0 FY20 FY21 FY22 FY23 FY24 FY25 FY20 FY21 FY22 FY23 FY24 FY25 ENIVO Other Capitalised Clinical Expenses1 Cash on Hand2 8 60 50 6 40 NZ$m NZ$m 4 30 20 2 10
Slide 14: Operations
Operations 15 | Confidential. Not for distribution.
Slide 15: Myriad
Myriad Large complex wounds (trauma) & lower 01 limb salvage procedures driving success Compelling clinical data Lower limb salvage (Lawlor1), Oral Surgery 02 (Su2, Mosquera3), Complex facial trauma (Dardano4) 03 Myriad Meshed v1 developed | Confidential. Not for distribution. 1. Lawlor, J. C., B. A
Slide 16: Myriad Outcomes
MYRIAD OUTCOMES Breakthrough Value 1 Restores Minimal Single tissue complications application Vascularized tissue coverage Low infection and graft A median of one 1-4 in as little as 7 days and loss rates, even in product application 1-4 1-8 volumetric fill in 3 weeks contaminated defects | Confiden
Slide 17: Symphony
Symphony 01 Complex chronic wounds Reimbursement uncertainty – reimbursed in hospital outpatient departments but not 02 physician offices. Launch paused - not constraining overall Aroa direct growth Randomised controlled trial - expected to 03 conclude Q3 2025 Likely to be reimbursed in physician 04
Slide 18: Symphony Advantages
SYMPHONY ADVANTAGES For the management of hard-to-heal wounds Progresses Designed for Supports continuum stalled wounds wound closure of outpatient care Broad spectrum immune AROA ECM and hyaluronic Along with Endoform, enables modulation enables the wound to acid work synergistically to all patient
Slide 19: OviTex
OviTex Compelling clinical evidence, 01 - low recurrence1-4 & explantation2, 5-10 rates Portfolio expansion - OviTex IHR, 02 Large PRS & LTR submission 03 FY’25 headwinds - strong future potential TELABio revenue - conservatively estimated 04 to grow at a moderate pace | Confidential. Not for distri
Slide 20: Strategy
Strategy 21 | Confidential. Not for distribution.
Slide 21: Substantial Growth Opportunities
Substantial Growth Opportunities > $3B1 TAM Total Addressable Market Total Addressable Market > $1.8B USD 2 > $1.3B USD 3 e.g. Diabetic Foot Ulcers, Venous e.g. Trauma, tumour removal, general e.g. Hernia repair, abdominal Ulcers, Pressure Ulcers, chronic wounds surgery, inflammatory skin disease de
Slide 22: Strategic focus
Strategic focus 23 | Confidential. Not for distribution.
Slide 23: Product strategy
Product strategy Enivo pre-clinical study to be followed by clinical study – up to 36 months to launch Improving healing rates & decreasing Improving healing complications rates & decreasing Soft Tissue complications Reconstruction & Hernia & Breast Chronic Wounds AROA ECM Restores tissue Minimal co
Slide 24: Outlook
Outlook 25 | Confidential. Not for distribution.
Slide 25: FY26 Guidance
FY26 Guidance1 NZ$92-100m NZ$5-8m Total Revenue Normalised EBITDA (YoY CC growth 10 – 20%) Myriad 25%+ | Confidential. Not for distribution. 1. All guidance is presented on a constant currency basis using a NZ$/US$ exchange rate of 0.60, compared to the average exchange rate of 0.59 in FY25. Constan
Slide 26: Focus
Focus THIS YEAR Large complex wounds (trauma) & lower limb salvage (Myriad) Myriad value proposition Deeper account penetration Faster sales ramp & increased productivity Wider use in hospital systems (IDNs) | Confidential. Not for distribution. 27
Slide 27: Milestones FY'26
Milestones FY’26 Demonstrate Myriad’s Secure Symphony One Myriad IDN distinctive value reimbursement in conversion physicians office Multiple hospitals Publish studies in Trauma, Pilonidal Sinus Disease, Burns Symphony RCT | Confidential. Not for distribution. 28
Slide 28: Questions & Answers
AROA BIOSURGERY Questions & Answers 29 | Confidential. Not for distribution.
Slide 29: Thank you for attending
Thank you for attending JAMES AGNEW m +64 21 744 915 investor@aroa.com VISIT www.aroa.com www.linkedin.com/company /aroa-biosurgery-limited/ 64 Richard Pearse Drive, | Confidential. Not for distribution. Auckland 2022, New Zealand PO Box 107111, Auckland Airport, Auckland 2150, New Zealand 30
Slide 30: Normalised Profit or Loss
APPENDIX Normalised Profit or Loss 1 Mar-25 Mar-24 Change Change Change (CC ) Reconcilliation between normalised profit or loss and NZ GAAP NZ$000 NZ$000 NZ$000 % % Product sales 83,977 67,966 16,011 24% 21% Mar-25 Mar-24 Other revenue 720 1,100 (380) -35% -38% NZ$000 NZ$000 Total revenue 84,697 69,
Slide 31: Normalised Cash flow
APPENDIX Normalised Cash flow1 Mar-25 Mar-24 Reconcilliation between normalised cash flow and NZ GAAP NZ$000 NZ$000 Cash flows from operating activities Mar-25 Mar-24 Cash receipts from sales revenue 76,648 65,247 NZ$000 NZ$000 Cash receipts from license fees, project fees, and grant income 2,032 2,
Slide 32: Balance Sheet
APPENDIX Balance Sheet Mar-25 Mar-24 NZ$000 NZ$000 Cash and cash equivalents 7,991 11,522 Term deposits 14,000 18,000 Trade and other receivables 16,327 13,437 Inventories 8,270 8,104 Prepayments 2,405 1,816 Contract assets 18,712 15,140 Tax receivable 312 313 Financial assets at fair value through